FDA Clears Mesoblast to Begin Pivotal Ryoncil Trial for Duchenne Muscular Dystrophy

The FDA's decision to grant Mesoblast an Investigational New Drug clearance that bypasses all exploratory phases is not a routine procedural step. It signals that the agency reviewed the company's preclinical evidence in DMD animal models and Ryoncil's existing pediatric safety record and judged the data strong enough to support a single, make-or-break registrational study. If the trial succeeds, Mesoblast can proceed directly to a Biologics License Application; if it fails, there is no intermediate study to fall back on.

The trial design reflects that high-stakes calculus. Mesoblast will randomize 76 patients aged 5 to 9 years to either seven intravenous infusions of Ryoncil at 2 million cells per kilogram over nine months, or placebo, on top of standard care. The primary endpoint is time-to-stand at nine months, a functional measure the FDA has validated for approval decisions in DMD. Aravindhan Veerapandiyan, director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital and the trial's principal investigator, said the study targets a window when muscle tissue may still be preserved. "By leveraging the anti-inflammatory effects of Ryoncil, we aim to intervene at a stage where muscle tissue may still be preserved, potentially altering the trajectory of the disease," he said.

Ryoncil occupies a mechanistically distinct corner of a crowded DMD pipeline. Where Sarepta Therapeutics' ELEVIDYS delivers a micro-dystrophin gene via AAV vector and Avidity Biosciences' del-zota uses an RNA-based exon-skipping approach targeting the genetic defect directly, Ryoncil is a mesenchymal stromal cell therapy designed to suppress the inflammatory and fibrotic cascade that destroys muscle tissue over time. Corticosteroids, still the backbone of standard DMD care, work on a similar immunosuppressive principle but carry well-documented long-term side effects in children. Mesoblast's argument is that Ryoncil, already FDA-approved for steroid-refractory acute graft-versus-host disease in children as young as two months, offers a cell-based alternative with a documented pediatric safety profile.

That existing approval, granted in December 2024, is the foundation for the IND clearance. The FDA has already reviewed Ryoncil's manufacturing process and safety data in pediatric patients; the DMD registrational study builds on that record rather than starting from scratch. "We are very pleased to have received clearance to proceed directly to a registrational study for DMD based on our preclinical data in DMD animal models and our extensive safety data in children with SR-aGvHD," said Mesoblast chief executive Silviu Itescu.

DMD is an X-linked genetic disorder caused by the absence of functional dystrophin, a structural protein essential to muscle integrity. The disease affects roughly 15,000 children in the United States, almost exclusively boys. Progressive degeneration of skeletal, respiratory and cardiac muscle typically leads to loss of ambulation in adolescence, respiratory failure, and death by the third decade of life.

To identify eligible patients ages 5 to 9, Mesoblast has contracted with Parent Project Muscular Dystrophy and the Duchenne Registry, two organizations with direct reach into the DMD community. For families considering enrollment, the most immediate practical question is access to trial sites; Veerapandiyan's program at Arkansas Children's Hospital is confirmed as one location, and additional sites are expected as the trial scales.

The cost question will loom over any eventual approval. Ryoncil currently carries a wholesale acquisition price of $194,000 per infusion for its SR-aGvHD indication. At that list price, the seven-infusion DMD regimen would approach $1.4 million, a figure likely to trigger intensive payer scrutiny even by the standards of the rare-disease market. Mesoblast has established patient assistance infrastructure under its MyMesoblast program for the SR-aGvHD indication, but whether that framework would extend to a DMD approval at comparable price points remains an open question the company has not yet addressed publicly.

The registrational study's nine-month active treatment window means top-line data could potentially be available within two to three years of enrollment completion, setting up a BLA submission and FDA review that, under standard timelines, could yield an approval decision before the end of the decade.